Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11239608 | 0.84 | TSHR (0.53) | KMT2AMEN1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL1810204 | 0.83 | KMT2A (0.61) | KMT2AMEN1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL11246059 | 0.82 | TSHR (0.55) | ALDH1A1L3MBTL1LMNAPOLBKDM4E | |
| SCHEMBL11238669 | 0.82 | TSHR (0.55) | ALDH1A1L3MBTL1LMNAPOLBKDM4E | |
| Isoorotic Acid Methyl Ester SCHEMBL7487788 | 0.80 | GAA (0.53) | KMT2AALDH1A1MAPTLMNAGAA | |
| SCHEMBL11240622 | 0.80 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1MAPTL3MBTL1 | |
| Isoorotic Acid Methyl Ester SCHEMBL11253390 | 0.79 | GAA (0.51) | KMT2AALDH1A1MAPTLMNAGAA | |
| SCHEMBL11237120 | 0.78 | KMT2A (0.43) | KMT2AALDH1A1MAPTL3MBTL1POLB | |
| SCHEMBL29029122 | 0.77 | KMT2A (0.44) | KMT2AALDH1A1MAPTLMNAPOLB | |
| SCHEMBL12050193 | 0.77 | GAA (0.45) | KMT2AALDH1A1MAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55102573-A | — | — | None | — | — | JP | disclosed |
| US-12421207-B2 | Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2025-09-23 | — | — | US | disclosed |
| US-20250171426-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2025-05-29 | — | — | US | disclosed |
| EP-4479397-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG Pharmaceutical Co., Ltd. (KR) | 2024-12-25 | — | — | EP | disclosed |
| CN-119032087-A | Pyrimidinedione-based compounds as AXL, C-MET and MER inhibitors and methods of use thereof | CMG制药株式会社 | 2024-11-26 | — | — | CN | disclosed |
| US-12054768-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240061153-A1 | REFLECTION-REDUCING LAYER SYSTEM WITH AN ELECTRICALLY CONDUCTIVE SURFACE AND METHOD FOR PRODUCING A REFLECTION-REDUCING LAYER SYSTEM | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2024-02-22 | — | — | US | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230348423-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348423-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| EP-0586523-A4 | DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF | UNIV YALE (US) | 1995-11-29 | — | — | EP | disclosed |
| EP-0586523-A1 | DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF | YALE UNIVERSITY (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| WO-1992020816-A1 | DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF | YALE UNIVERSITY (US) | 1992-11-26 | — | — | WO | disclosed |
| US-4975434-A | Antiviral and anticancer cyclopentenyl cytosine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1990-12-04 | — | — | US | disclosed |
| US-4968690-A | 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it | UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES (US) | 1990-11-06 | — | — | US | disclosed |
| WO-1990009177-A1 | CYCLOPENTENYL PYRIMIDINES AND METHODS OF USING SAME | US ARMY (US) | 1990-08-23 | — | — | WO | disclosed |
| US-4329460-A | ANTICANCER AGENTS, ANTIVIRAL AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-05-11 | — | — | US | disclosed |
| JP-S55102573-A | PREPARATION OF URACIL DERIVATIVE | TAKEDA CHEM IND LTD | 1980-08-05 | — | — | JP | disclosed |
| US-4190656-A | VIRICIDES, ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171426-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, AXL, RET | KMT2A 1790/4885MEN1 228/4885ALDH1A1 2111/4885 |
| US-12421207-B2 | Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof | MERTK, AXL, MET | KMT2A 2233/4885MEN1 216/4885ALDH1A1 2154/4885 |
| US-20230348423-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, AXL, MET | KMT2A 2233/4885MEN1 216/4885ALDH1A1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.